Product Description

Lorlatinib is the third generation of asexual lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), which is applicable to the treatment of ALK positive patients with metastatic non-small cell lung cancer (NSCLC). The disease of these patients has progressed before a) when using clototinib and at least one other ALK inhibitor to treat metastatic diseases. Or b) Elotinib was previously used as the first ALK inhibitor for the treatment of metastatic diseases, or c) Clozotinib was previously used as the first ALK inhibitor for the treatment of metastatic diseases.